Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Am J Pathol ; 175(6): 2430-8, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19850890

ABSTRACT

Recent reports suggest that commensal bacteria may play a down-regulatory role in autoimmune disease. In the present studies, we demonstrate that phosphorylated dihydroceramides, uniquely structured lipids derived from the common human oral bacterium Porphyromonas gingivalis and from bacteria commonly found in the gastrointestinal tract and other organs, are capable of enhancing autoimmunity. We have previously reported that these lipids have proinflammatory effects on human fibroblasts in vitro and, in preliminary studies, have recovered these lipids from surgically removed human carotid atheroma, suggesting that they may play a role in human inflammatory disease. To investigate whether these lipids have functional effects on autoimmunity, we administered phosphorylated dihydroceramides to mice with the murine model of multiple sclerosis, experimental allergic encephalomyelitis (EAE). We find that these lipids, and particularly the phosphoethanolamine dihydroceramide (PE DHC) fraction, significantly enhanced EAE. Mechanistically, PE DHC enhances EAE in mice lacking natural killer T cells, fails to enhance EAE in Toll-like receptor 2 (TLR2)-deficient mice and, in vitro, induces dendritic cell interleukin-6 secretion in a TLR2-dependent manner. Finally, PE DHC-treated mice with EAE demonstrate a decreased percentage of spinal cord Foxp3+ T cells, suggesting that these lipids may affect regulatory aspects of adaptive immune responses. Overall, our results suggest that phosphorylated dihydroceramides derived from common human bacteria function as TLR2 ligands and may play a previously unrecognized role in human autoimmune diseases.


Subject(s)
Autoimmunity , Ceramides/immunology , Encephalomyelitis, Autoimmune, Experimental/immunology , Lipids/immunology , Toll-Like Receptor 2/immunology , Animals , Dendritic Cells/immunology , Dendritic Cells/metabolism , Female , Humans , Ligands , Mice , Mice, Inbred C57BL , Mice, Knockout , Porphyromonas gingivalis/immunology , T-Lymphocytes/immunology
2.
J Leukoc Biol ; 86(2): 293-301, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19401386

ABSTRACT

CD4+ CD25+ Foxp3+ Tregs are critical regulators of immune responses and autoimmune diseases. nTregs are thymically derived; iTregs are converted in the periphery from CD4+ CD25- Foxp3- Teffs. Recent studies reported that GALT CD103+ DCs mediated enhanced iTreg conversion via the secretion of RA. However, the factors regulating RA secretion and hence, the induction of iTregs by DCs are not yet clear. Activation of the nuclear hormone receptor PPARgamma has been shown to induce RA expression in human DCs, and thus, we postulated that PPARgamma activation in DCs may be an important regulator of RA secretion and iTreg generation. Using in vitro and in vivo approaches, we now demonstrate that PPARgamma activation enhances iTreg generation through increased RA synthesis from murine splenic DCs. In addition, we demonstrate that inhibition of DC PPARgamma decreases iTreg generation, suggesting a role for endogenous PPARgamma ligands in this process. Overall, our findings suggest that PPARgamma may be important as a factor that stimulates DCs to produce RA and as a potential mechanism by which PPARgamma ligands ameliorate autoimmunity.


Subject(s)
Dendritic Cells/metabolism , Immune Tolerance/immunology , Immunologic Factors/metabolism , PPAR gamma/metabolism , T-Lymphocytes, Regulatory/immunology , Tretinoin/metabolism , Active Transport, Cell Nucleus/immunology , Animals , Autoimmunity/immunology , Cell Communication/immunology , Down-Regulation/immunology , Mice , Mice, Transgenic , Receptors, Cytoplasmic and Nuclear/metabolism , Signal Transduction/immunology
3.
Blood ; 110(1): 142-50, 2007 Jul 01.
Article in English | MEDLINE | ID: mdl-17363739

ABSTRACT

CD13/aminopeptidase N is a transmembrane peptidase that is induced in the vasculature of solid tumors and is a potent angiogenic regulator. Here, we demonstrate that CD13 controls endothelial cell invasion in response to the serum peptide bradykinin by facilitating signal transduction at the level of the plasma membrane. Inhibition of CD13 abrogates bradykinin B(2) receptor internalization, leading to the attenuation of downstream events such as bradykinin-induced activation of Cdc42 and filopodia formation, and thus affects endothelial cell motility. Investigation into mechanisms underlying this block led us to focus on B(2)R internalization via membrane-dependent mechanisms. Membrane disruption by depletion of cholesterol or trypsinization halts B(2)R internalization, invasion, and filopodia formation, which can be recovered with addition of cholesterol. However, this functional recovery is severely impaired in the presence of CD13 antagonists, and the distribution of membrane proteins is disordered in treated cells, suggesting a role for CD13 in plasma membrane protein organization. Finally, exogenous expression of wild-type but not mutant CD13 further alters protein distribution, suggesting peptidase activity is required for CD13's regulatory activity. Therefore, CD13 functions as a novel modulator of signal transduction and cell motility via its influence on specific plasma membrane organization, thus regulating angiogenesis.


Subject(s)
CD13 Antigens/physiology , Cell Movement , Endothelial Cells/cytology , Neovascularization, Physiologic , Pseudopodia/ultrastructure , Receptor, Bradykinin B2/physiology , Bradykinin/pharmacology , Cells, Cultured , Endocytosis , Endothelium, Vascular/cytology , Humans , Signal Transduction
SELECTION OF CITATIONS
SEARCH DETAIL
...